Patents by Inventor Laura M. Hales

Laura M. Hales has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic vitamin D conjugates
    Patent number: 12076366
    Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.
    Type: Grant
    Filed: July 3, 2020
    Date of Patent: September 3, 2024
    Assignee: Extend Biosciences, Inc.
    Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
  • Therapeutic vitamin d conjugates
    Patent number: 11116816
    Abstract: The invention provides a parathyroid hormone (PTH) compound comprising a PTH peptide. The PTH compound has a significantly increased bioavailability or circulating half-life when compared to a bioavailability or a circulating half-life of a native form of the PTH peptide. The PTH compound has a significantly greater serum concentration at multiple timepoints post-administration to a rat when compared to that of a native PTH peptide.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: September 14, 2021
    Assignee: Extend Biosciences, Inc.
    Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
  • THERAPEUTIC VITAMIN D CONJUGATES
    Publication number: 20210008153
    Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.
    Type: Application
    Filed: July 3, 2020
    Publication date: January 14, 2021
    Applicant: Extend Biosciences, Inc.
    Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
  • Therapeutic vitamin D conjugates
    Patent number: 10702574
    Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.
    Type: Grant
    Filed: February 11, 2017
    Date of Patent: July 7, 2020
    Assignee: Extend Biosciences, Inc.
    Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
  • Insulin vitamin D conjugates
    Patent number: 10420819
    Abstract: The invention provides non-hormonal vitamin D conjugated to insulin peptides that result in the peptides having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the insulin peptides via the third carbon on the vitamin D backbone.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: September 24, 2019
    Assignee: Extend Biosciences, Inc.
    Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Howard Sard, Vishnumurthy Hegde
  • Therapeutic vitamin D conjugates
    Patent number: 10406202
    Abstract: The invention provides non-hormonal vitamin D conjugated via the third carbon on the vitamin D backbone to parathyroid hormone (PTH) proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: September 10, 2019
    Assignee: Extend Biosciences, Inc.
    Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
  • THERAPEUTIC VITAMIN D CONJUGATES
    Publication number: 20190183966
    Abstract: The invention provides a parathyroid hormone (PTH) compound comprising a PTH peptide. The PTH compound has a significantly increased bioavailability or circulating half-life when compared to a bioavailability or a circulating half-life of a native form of the PTH peptide. The PTH compound has a significantly greater serum concentration at multiple timepoints post-administration to a rat when compared to that of a native PTH peptide.
    Type: Application
    Filed: January 29, 2019
    Publication date: June 20, 2019
    Applicant: Extend Biosciences, Inc.
    Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
  • THERAPEUTIC VITAMIN D CONJUGATES
    Publication number: 20180311307
    Abstract: The invention provides non-hormonal vitamin D conjugated via the third carbon on the vitamin D backbone to parathyroid hormone (PTH) proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms.
    Type: Application
    Filed: July 12, 2018
    Publication date: November 1, 2018
    Applicant: Extend Biosciences, Inc.
    Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
  • Carriers for improved drug delivery
    Patent number: 9884124
    Abstract: The invention provides carriers that enhance the absorption, half-life or bioavailability of therapeutic compounds. The carriers comprise targeting groups that bind the Vitamin D Binding protein (DBP), conjugation groups for coupling the targeting groups to the therapeutic compounds, and optionally scaffolding moieties.
    Type: Grant
    Filed: February 6, 2016
    Date of Patent: February 6, 2018
    Assignee: Extend Biosciences, Inc.
    Inventors: Tarik Soliman, Laura M. Hales, Howard P. Sard, Mukkanti Amere
  • RNAi vitamin D conjugates
    Patent number: 9789197
    Abstract: The invention provides non-hormonal vitamin D conjugated to therapeutic RNA compounds that result in the compounds having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the therapeutic RNA compounds via the third carbon on the vitamin D backbone.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: October 17, 2017
    Assignee: Extend Biosciences, Inc.
    Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Howard P. Sard, Vishnumurthy Hegde
  • INSULIN VITAMIN D CONJUGATES
    Publication number: 20170252410
    Abstract: The invention provides non-hormonal vitamin D conjugated to insulin peptides that result in the peptides having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the insulin peptides via the third carbon on the vitamin D backbone.
    Type: Application
    Filed: March 23, 2017
    Publication date: September 7, 2017
    Applicant: Extend Biosciences, Inc.
    Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Howard Sard, Vishnumurthy Hegde
  • THERAPEUTIC VITAMIN D CONJUGATES
    Publication number: 20170216449
    Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.
    Type: Application
    Filed: February 11, 2017
    Publication date: August 3, 2017
    Applicant: Extend Biosciences, Inc.
    Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
  • Insulin vitamin D conjugates
    Patent number: 9616109
    Abstract: The invention provides non-hormonal vitamin D conjugated to insulin peptides that result in the peptides having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the insulin peptides via the third carbon on the vitamin D backbone.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: April 11, 2017
    Assignee: Extend Biosciences, Inc.
    Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Howard Sard, Vishnumurthy Hegde
  • Therapeutic vitamin D conjugates
    Patent number: 9585934
    Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: March 7, 2017
    Assignee: Extend Biosciences, Inc.
    Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
  • CARRIERS FOR IMPROVED DRUG DELIVERY
    Publication number: 20160144049
    Abstract: The invention provides carriers that enhance the absorption, half-life or bioavailability of therapeutic compounds. The carriers comprise targeting groups that bind the Vitamin D Binding protein (DBP), conjugation groups for coupling the targeting groups to the therapeutic compounds, and optionally scaffolding moieties.
    Type: Application
    Filed: February 6, 2016
    Publication date: May 26, 2016
    Applicant: Extend Biosciences, Inc.
    Inventors: Tarik Soliman, Laura M. Hales, Howard P. Sard, Mukkanti Amere
  • RNAi VITAMIN D CONJUGATES
    Publication number: 20160114049
    Abstract: The invention provides non-hormonal vitamin D conjugated to therapeutic RNA compounds that result in the compounds having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the therapeutic RNA compounds via the third carbon on the vitamin D backbone.
    Type: Application
    Filed: October 21, 2015
    Publication date: April 28, 2016
    Applicant: EXTEND BIOSCIENCES, INC.
    Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Howard P. Sard, Vishnumurthy Hegde
  • THERAPEUTIC VITAMIN D CONJUGATES
    Publication number: 20160113993
    Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.
    Type: Application
    Filed: October 21, 2015
    Publication date: April 28, 2016
    Applicant: EXTEND BIOSCIENCES, INC.
    Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
  • INSULIN VITAMIN D CONJUGATES
    Publication number: 20160114001
    Abstract: The invention provides non-hormonal vitamin D conjugated to insulin peptides that result in the peptides having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the insulin peptides via the third carbon on the vitamin D backbone.
    Type: Application
    Filed: October 21, 2015
    Publication date: April 28, 2016
    Applicant: EXTEND BIOSCIENCES, INC.
    Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Howard Sard, Vishnumurthy Hegde
  • Carriers for improved drug delivery
    Patent number: 9289507
    Abstract: The invention provides carriers that enhance the absorption, half-life or bioavailability of therapeutic compounds. The carriers comprise targeting groups that bind the Vitamin D Binding protein (DBP), conjugation groups for coupling the targeting groups to the therapeutic compounds, and optionally scaffolding moieties.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: March 22, 2016
    Assignee: Extend Biosciences, Inc.
    Inventors: Tarik Soliman, Laura M. Hales, Howard P. Sard, Mukkanti Amere
  • Vitamin D-ghrelin conjugates
    Patent number: 9173950
    Abstract: The invention provides carriers that enhance the absorption, half-life or bioavailability of Ghrelin peptides. The carriers comprise targeting groups that bind the Vitamin D Binding protein (DBP), conjugation groups for coupling the targeting groups to the therapeutic compounds, and optionally scaffolding moieties.
    Type: Grant
    Filed: November 15, 2014
    Date of Patent: November 3, 2015
    Assignee: Extend Biosciences, Inc.
    Inventors: Tarik Soliman, Laura M. Hales, Howard P. Sard, Mukkanti Amere